The Center for Diseases Modeling and Program in Molecular and Cell Biology, Zhejiang University School of Medicine, Hangzhou, China.
Cell Res. 2010 Jul;20(7):784-93. doi: 10.1038/cr.2010.79. Epub 2010 Jun 15.
Emerging evidence has shown the association of aberrantly expressed microRNAs (miRNAs) with tumor development and progression. However, little is known about the potential role of miRNAs in gastric carcinogenesis. Here, we performed miRNA microarray to screen miRNAs differentially expressed in the paired gastric cancer and their adjacent nontumor tissues and found that miR-375 was greatly downregulated in gastric cancer tissues. Quantitative real-time PCR analysis verified that miR-375 expression was significantly decreased in more than 90% of primary gastric cancers compared with their nontumor counterparts from patients undergoing gastric resection. Overexpression of miR-375 significantly inhibited gastric cancer cell proliferation in vitro and in vivo. Forced expression of miR-375 in gastric cancer cells significantly reduced the protein level of Janus kinase 2 (JAK2) and repressed the activity of a luciferase reporter carrying the 3'-untranslated region of JAK2, which was abolished by mutation of the predicted miR-375-binding site, indicating that JAK2 may be a miR-375 target gene. Either inhibition of JAK2 activity by AG490 or silencing of JAK2 by RNAi suppressed gastric cancer cell proliferation resembling that of miR-375 overexpression. Moreover, ectopic expression of JAK2 can partially reverse the inhibition of cell proliferation caused by miR-375. Finally, we found a significant inverse correlation between miR-375 expression and JAK2 protein level in gastric cancer. Thus, these data suggest that miR-375 may function as a tumor suppressor to regulate gastric cancer cell proliferation potentially by targeting the JAK2 oncogene, implicating a role of miR-375 in the pathogenesis of gastric cancer.
新出现的证据表明,异常表达的 microRNAs(miRNAs)与肿瘤的发生和发展有关。然而,miRNAs 在胃癌发生中的潜在作用知之甚少。在这里,我们进行了 miRNA 微阵列分析,以筛选在配对的胃癌及其相邻非肿瘤组织中差异表达的 miRNAs,发现 miR-375 在胃癌组织中显著下调。定量实时 PCR 分析验证了 miR-375 在超过 90%的原发性胃癌组织中的表达明显低于接受胃切除术的患者的非肿瘤对应物。miR-375 的过表达显著抑制了体外和体内胃癌细胞的增殖。在胃癌细胞中强制表达 miR-375 显著降低了 Janus 激酶 2(JAK2)的蛋白水平,并抑制了携带 JAK2 3'-非翻译区的荧光素酶报告基因的活性,该活性被预测的 miR-375 结合位点的突变所消除,表明 JAK2 可能是 miR-375 的靶基因。通过 AG490 抑制 JAK2 活性或通过 RNAi 沉默 JAK2 抑制胃癌细胞增殖,类似于 miR-375 的过表达。此外,外源性表达 JAK2 可以部分逆转 miR-375 引起的细胞增殖抑制。最后,我们发现 miR-375 表达与胃癌中 JAK2 蛋白水平之间存在显著的负相关。因此,这些数据表明,miR-375 可能通过靶向 JAK2 致癌基因作为肿瘤抑制因子发挥作用,调节胃癌细胞增殖,这意味着 miR-375 在胃癌发病机制中起作用。